CompletedNot Applicable

Standalone Observational Study Assessing the Performance of an AI/ML Tech-based SaMD on Chest LDCT Images (REALITY)

United States, Spain1,147 participantsStarted 2022-09-21

Plain-language summary

This is a Multinational, Multicenter, retrospective study for the evaluation of the standalone efficacy and safety of an Artificial Intelligence/Machine Learning (AI/ML) technology-based end-to-end Computer assisted Detection/Computer Assisted Diagnosis (CADe/CADx) Software as a Medical Device (SaMD) developed to detect, localize and characterize malignant, and suspicious for lung cancer nodules on Low Dose Computed Tomography (LDCT) scans taken as part of a Lung Cancer Screening (LCS) program. LDCT Digital Imaging and Communications in Medicine (DICOM) images of patients who underwent lung cancer screening were selected and included into the study. Selected scans will then be analyzed by the CADe/CADx SaMD and compared to radiologist generated reference standards including lesions localization and lesion cancer diagnosis. Figures of merit at patient level and lesion level detection and diagnostic efficacy will be calculated as well as sub-class analysis to ensure algorithm performance generalizability.

Who can participate

Age range50 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ≥50-80 Years of age; * Current or ex-smoker (\>=20 pack years); * Patient screened and surveilled for lung cancer screening following lung cancer screening guidelines (equivalent to United States Preventive Services Task Force (USPSTF) 2021 Criteria); * Received LDCT due to inclusion in high-risk category for lung cancer. Exclusion Criteria: * Prior lung resection; * Pacemaker or other indwelling metallic medical devices in the thorax that interfere with CT acquisition; * Patients/images used during AI model development; * Patients with only hilar and/or mediastinal cancer(s); * Patients with only ground glass cancer(s); * Patients with nodules, solid or part-solid \>30mm (masses); * Patients that are not accompanied with the required clinical information; * Patients with imaging with any of the following: missing slices, slice thickness \>3mm; * Partial cover of the lung.

What they're measuring

AUROC (Area under ROC curve) at patient level

Timeframe: 12 months

Trial details

NCT IDNCT06576232

SponsorMedian Technologies

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-07-24